Company: INDP
Filing Date: 2025-06-13
Form Type: 8-K
Source: 0001641172-25-014972
Chunk: 1

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-06-13
Form: 8-K
Item: Item 1.01
Chunk 1
---
 each Purchaser will receive a Warrant
exercisable for shares of the Company’s Common Stock in a number equal to (i) 200% of the Conversion Shares if they subscribed
on or before the close of business on June 30, 2025 or (ii) 100% of the Conversion Shares if they subscribed after June 30, 2025. The
Warrants are exercisable on the date which is the later of (i) the Conversion Date and (ii) the date stockholder approval is obtained
and will expire on the five year anniversary thereafter. The Warrants will have an exercise price equal to the Conversion Price. Pursuant
to the Purchase Agreements, the Company has agreed to file a registration statement within 30 days of the Conversion Date providing for
the resale of the Conversion Shares and shares of Common Stock underlying the Warrants (the “ Warrant Shares”). The Company
has also agreed to use commercially reasonable efforts to cause such registration statement to become effective within 60 days following
the Conversion Date and to use commercially reasonable efforts to keep such registration statement effective at all times until the earlier
of (i) the date that no Purchaser owns any Conversion Shares, Warrants or Warrant Shares issuable upon exercise thereof and (ii) the
two year anniversary of the closing date.

In
compliance with Nasdaq Listing Rule 5635(d), the Company and the Purchasers agreed that the Company will not issue Convertible Shares
if it would exceed the aggregate number of shares of Common Stock which the Company may issue upon conversion of the Convertible Notes
without breaching the Company’s obligations under Nasdaq Listing Rule 5635(d). Pursuant to the Purchase Agreement, the Company
agreed to hold a special stockholder meeting in order to seek stockholder approval.

The
foregoing descriptions of the Purchase Agreement, Notes and Warrants are qualified by reference to the full text of such documents, a
form of each of which are filed as Exhibits 10.1, 10.2 and 10.3 to this Current Report on Form 8-K and are incorporated by reference
herein.

Paulson
Investment Company, LLC (“ Paulson”) served as the exclusive placement agent for the issuance and sale of securities of the
Company pursuant to a Placement Agent Agreement (the “ PAA”) between the Company and Paulson. As compensation for such placement
agent services, the Company has agreed to pay Paulson an aggregate cash fee equal